Replies to post #20499 on Ayala Pharmaceuticals Inc (ADXS)

[attilathehunt]

This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status

Perhaps it means we need to provide the latest trial updates a week prior to decision meeting to ensure current data is good as of the date of EMA submission. Just a guess.